Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01956812 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
A Phase 3 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 334
- Enrollment target
NCT01956812: Clinical Trial Phase 3 study, sponsored by Gilead Sciences.
NCT01956812 is a Phase 3 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 334 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01956812, a Phase 3 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 334 participants
- Enrollment target
Study Summary
The is a double-blind, randomized phase 3 study of 90Y-clivatuzumab tetraxetan with low-dose gemcitabine, versus placebo and low-dose gemcitabine in metastatic pancreatic cancer patients who have progressed on at least 2 prior therapies for metastatic cancer (1 of which was a gemcitabine-containing regimen).
Interventions
- DRUG placebo
- DRUG Gemcitabine
- DRUG IMMU-107
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 334 participants |
| Start Date | 2013-12 |
| Est. Completion | 2016-11 |
| Phase | Phase 3 |
Why NCT01956812 stopped before completion
NCT01956812 is an interventional study that assigns participants to a tested intervention. The registered 334 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01956812 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01956812 about?
NCT01956812 is a clinical study titled "Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer". The is a double-blind, randomized phase 3 study of 90Y-clivatuzumab tetraxetan with low-dose gemcitabine, versus placebo and low-dose gemcitabine in metastatic pancreatic cancer patients who have progressed on at least 2 prior therapies for metastatic cancer (1 of which was a gemcitabine-containing ...
What is the current status of trial NCT01956812?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 334 participants. The study started on 2013-12. Estimated completion is 2016-11.
What interventions are being tested in trial NCT01956812?
The interventions under investigation include: placebo (DRUG), Gemcitabine (DRUG), IMMU-107 (DRUG).
Who is sponsoring clinical trial NCT01956812?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01956812's enrollment target sits among peer trials
334 1061st of 2000 higher than 940 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05131672 · 334 participants · NA
Cast or Operation for Medial Epicondyle Fracture Treatment in Children
- NCT05131685 · 334 participants · NA
Distal Radius Interventions for Fracture Treatment
- NCT05546931 · 334 participants · NA
Mobile Health Program for Rural Hypertension
- NCT05722197 · 334 participants · NA
Assessment of Emotion Regulation Strategies Used When Suicidal
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia